Challenges in developing antidrug antibody screening assays

Bioanalysis

Volumn 1, Issue 4, 2009, Pages 699-704

  Dodge, Robert ^a   Daus, Caroline ^a   Yaskanin, Dania ^a  

^a PharmaNet Development Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; NEUTRALIZING ANTIBODY; PROTEIN;

HUMAN; IMMUNOASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; REVIEW;

ANTIBODIES, NEUTRALIZING; HUMANS; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 79953013563     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.55     Document Type: Article

References (24)

1. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part I: considering consequences of the immune response to a protein. Biopharm. Intl 17(11), 22-26 (2004).
2. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007)
3. EMEA guideline on similar biological medicinal products. Doc. Ref. CHMP/437/04 (2005).
4. Mire-Sluis AR, Barrett C, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004)
5. EMEA guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006
6. Geng D, Shankar G, Schantz A et al. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39, 364-375 (2005).
7. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualifcation of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321, 1-18 (2007).
8. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
9. Mason S, La S, Mytych D et al. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr. Med. Res. Opin. 19, 651-659 (2003).
10. Rup B, O'Hara D. Critical ligand binding reagent preparation/selection: when specifcity depends on reagents. AAPS J. 9(2), 16 E148 (2007).
11. Gross J, Moller R, Henke W, Hoesel W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J. Immunol. Methods 313, 176-182 (2006).
12. ® (galsulfase). AAPS J. 10(2), 363-372 (2008).
13. Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the t cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J. Rheumatol. 34, 2365-2373 (2007).
14. Awwad M. Nature of immunoassay interference. Presented at: National Biotechnology Conference. San Diego, CA, USA 24-27 June 2007.
15. Bautista AC, Yue E, Chirmule N, Swanson S, Jawa V. Elimination of rheumatoid factor interference in immunoassays using the electrochemical (ECL) based Meso Scale Discovery (MSD) platform. FASEB J. 22, lb566 (2008).
16. Nadar A, Gupta S, Kaliyaperumal A et al. Validation of a cell based assay to detect antidrug neutralizing antibodies in cynomolgus monkey serum pretreated with Pierce Melon Gel™. Presented at: National Biotechnology Conference. San Francisco, CA, USA 5-8 June 2005.
17. Subramanyam M. Case study: immunogenicity of natalizumab. In: Immunogenicity of Biopharmaceuticals. Van de Weert M, Moller EH (Eds). Springer AAPS Press, The Netherlands (2008).
18. Peng K, Siradze K, Araujo J et al. Comparison of assay technologies for immunogenicity measurement. Presented at: National Biotechnology Conference. Toronto, ON, Canada June 23-24, 2008.
19. European Public Assessment Report (EPAR) Omnitrope (EMEA/H/C/607). Scientifc discussion. EMEA (2006).
20. Guo X, Fasulo LM, Finco-Kent D et al. Evaluation of assays for the detection of primary anti-human antibodies: ECL vs. ELISA. Presented at: National Biotechnology Conference. Boston, MA, USA 18-21 June 2006.
21. Sickert D, Kroeger K, Zickler C et al. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J. Immunol. Methods 334(1-2), 29-36 (2008).
22. Smith H W, Butterfeld A, Sun D et al. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol. 49, 230-237 (2007).
23. Neubert H, Grace C, Rumpel K et al. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal. Chem. 80(18), 907-6914 (2008).
24. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specifc for galactose-a-1, 3-galactose. N. Engl. J. Med. 358, 1109-1117 (2008).